Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 1699–1705 | Cite as

PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma

Original Article

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignancies in the world. Numerous studies have linked the activation of AKT to the progression of PDAC. Phosphatidylethanolamine-binding protein 4 (PEBP4) has been reported to be upregulated in various cancer types. However, its expression pattern and biological functions in PDAC are unknown. In this study, it was found that the messenger RNA (mRNA) and protein level of PEBP4 was elevated in PDAC samples. Forced expression of PEBP4 in PDAC cell lines promoted cell growth and migration, while downregulation of PEBP4 in PDAC cells by RNA interference (RNAi) inhibited the growth, migration, and metastasis of the cancer cells. PEBP4 interacted with AKT and promoted the phosphorylation of serine 473 in AKT. Collectively, this study suggested that PEBP4 might promote the progression of PDAC through activating AKT signaling and PEBP4 might be a promising therapeutic target for PDAC treatment.

Keywords

PEBP4 PDAC AKT Cell growth and migration 

Notes

Acknowledgments

This work was supported by the findings from the National Natural Science Foundation of China (81272728), Shanghai Municipal Commission of Health and Family Planning (201440338), Shanghai Minhang District Commission of Science and Technology (2014MW22), and Shanghai Minhang District Commission of Science and Technology (2011MHZ06, 2011MHZ25).

Conflicts of interest

None

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of pancreatic cancer. Cancer J. 2015;21:188–93.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Seicean A, Petrusel L, Seicean R. New targeted therapies in pancreatic cancer. World J Gastroenterol. 2015;21:6127–45.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mabuchi S, Kuroda H, Takahashi R, Sasano T. The pi3k/akt/mtor pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137:173–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Cheaib B, Auguste A, Leary A. The pi3k/akt/mtor pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34:4–16.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G. Pi3k/akt/mtor signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine. 2015;48:363–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Yip PY. Phosphatidylinositol 3-kinase-akt-mammalian target of rapamycin (pi3k-akt-mtor) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:165–76.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y, Farajnia S. Natural inhibitors of pi3k/akt signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res. 2015;93:1–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the pi3k/akt pathway in colorectal cancer. Biochim Biophys Acta. 2015;1855:104–21.PubMedGoogle Scholar
  10. 10.
    Xia S, Feng Z, Qi X, Yin Y, Jin J, Wu Y, et al. Clinical implication of sox9 and activated akt expression in pancreatic ductal adenocarcinoma. Med Oncol. 2015;32:358.CrossRefPubMedGoogle Scholar
  11. 11.
    Ling HH, Mendoza-Viveros L, Mehta N, Cheng HY. Raf kinase inhibitory protein (rkip): functional pleiotropy in the mammalian brain. Crit Rev Oncog. 2014;19:505–16.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bian JM, Wu N, Li J. Roles of phosphatidylethanolamine-binding protein in cell signaling and its biological functions. Sheng Li Xue Bao. 2013;65:237–43.PubMedGoogle Scholar
  13. 13.
    Keller ET, Fu Z, Brennan M. The role of raf kinase inhibitor protein (rkip) in health and disease. Biochem Pharmacol. 2004;68:1049–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Parveen Z, Bibi Z, Bibi N, Neesen J, Rashid S. Disruption of murine tcte3-3 induces tissue specific apoptosis via co-expression of anxa5 and pebp1. Comput Biol Chem. 2014;53PB:214–25.CrossRefPubMedGoogle Scholar
  15. 15.
    Yu G, Shen Z, Chen G, Teng X, Hu Y, Huang B. Pebp4 enhanced hcc827 cell proliferation and invasion ability and inhibited apoptosis. Tumour Biol. 2013;34:91–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Yu G, Zhong N, Chen G, Huang B, Wu S. Downregulation of pebp4, a target of mir-34a, sensitizes drug-resistant lung cancer cells. Tumour Biol. 2014;35:10341–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhao Z, Zhang L, Yao Q, Tao Z. Mir-15b regulates cisplatin resistance and metastasis by targeting pebp4 in human lung adenocarcinoma cells. Cancer Gene Ther. 2015;22:108–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu H, Kong Q, Li B, He Y, Li P, Jia B. Expression of pebp4 protein correlates with the invasion and metastasis of colorectal cancer. Tumour Biol. 2012;33:267–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Yu GP, Huang B, Chen GQ, Wu S, Ji Y, Shen ZY. Pebp4 gene expression and its significance in invasion and metastasis of non-small cell lung cancer. Tumour Biol. 2012;33:223–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu GP, Chen GQ, Wu S, Shen K, Ji Y. The expression of pebp4 protein in lung squamous cell carcinoma. Tumour Biol. 2011;32:1257–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia R, Grindlay J, Rath O, Fee F, Kolch W. Regulation of human myoblast differentiation by pebp4. EMBO Rep. 2009;10:278–84.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chang Z, Ju H, Ling J, et al. Cooperativity of oncogenic k-ras and downregulated p16/ink4a in human pancreatic tumorigenesis. PLoS One. 2014;9:e101452.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials. Anti Cancer Agents Med Chem. 2011;11:455–63.CrossRefGoogle Scholar
  24. 24.
    Morran DC, Wu J, Jamieson NB, et al. Targeting mtor dependency in pancreatic cancer. Gut. 2014;63:1481–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rozengurt E. Mechanistic target of rapamycin (mtor): a point of convergence in the action of insulin/igf-1 and g protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol. 2014;5:357.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Duluc C, Moatassim-Billah S, Chalabi-Dchar M, et al. Pharmacological targeting of the protein synthesis mtor/4e-bp1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015;7:735–53.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dexiang Zhang
    • 1
  • Yuedi Dai
    • 2
  • Yuankun Cai
    • 1
  • Tao Suo
    • 3
  • Han Liu
    • 3
  • Yueqi Wang
    • 3
  • Zhijian Cheng
    • 1
  • Houbao Liu
    • 3
  1. 1.General Surgery DepartmentThe Fifth People’s Hospital of Shanghai, Fudan UniversityShanghaiChina
  2. 2.Department of Medical OncologyCancer Hospital of Fudan UniversityShanghaiChina
  3. 3.General Surgery Department, General Surgery InstituteZhongshan Hospital, Fudan UniversityShanghaiChina

Personalised recommendations